{"filings":[{"id":1468556,"accession_number":"0001703057-26-000037","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-07-06T18:53:55+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera appoints Dr. Lynn Seely to Board of Directors as independent Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lynn Seely appointed as Class III director effective June 30, 2026, serving until 2029 annual meeting.","She is independent under Nasdaq rules and will receive standard non-employee director compensation.","Dr. Seely is President and CEO of Lyell Immunopharma, former CEO of Myovant Sciences, and former CMO of Medivation.","Her experience includes endocrinology, oncology, and women's health, relevant to AbCellera's antibody-based medicine development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1102716,"accession_number":"0001703057-26-000035","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-06-17T16:38:25+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera announces $56M upfront collaboration with Jazz Pharma for T-cell engager antibodies","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$56M upfront for first two programs; $28M additional upon initiation of third program within 12 months.","Up to $792M per program in option fees and milestones plus mid-single to low-double-digit royalties on net sales.","Collaboration targets gastrointestinal cancers and other solid tumors using AbCellera's T-cell engaging multispecific platform.","Jazz holds exclusive worldwide rights to develop and commercialize after exercising option for each program.","AbCellera may also conduct IND-enabling studies and manufacture clinical supply for programs under the collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1017916,"accession_number":"0001703057-26-000033","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-06-12T16:12:02+00:00","items":["5.07"],"status":"ready","headline":"AbCellera shareholders elect two Class III directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John S. Montalbano elected with 141.4M for, 12.7M against; Stephen R. Quake with 149.0M for, 5.1M against.","Ratification of Ernst & Young as independent auditor for FY2026: 190.0M for, 0.6M against.","Advisory say-on-pay approved: 142.8M for, 10.9M against, with 36.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":878516,"accession_number":"0001703057-26-000031","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-06-05T16:03:46+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera appoints Dr. Victor Sandor as independent director to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Victor Sandor, M.D.C.M., to Board as independent director effective June 1, 2026.","Dr. Sandor brings oncology drug development expertise; previously CMO at Array BioPharma.","He secured approval of Braftovi and Mektovi at Array and contributed to Jakafi and Faslodex development.","Sandor currently serves on boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics.","Will not serve on any board committees initially; compensated per non-employee director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13126,"accession_number":"0001703057-26-000027","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-05-11T20:11:11+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.","Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).","ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.","ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.","Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":8315000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107479,"accession_number":"0001703057-26-000010","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera FY2025 revenue $75.1M, net loss $146.4M; liquidity ~$700M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.1M vs $28.8M YoY; net loss $146.4M vs $162.9M; EPS $(0.49) vs $(0.55).","Available liquidity ~$700M ($561M cash + $135M non-dilutive govt funding).","Advanced ABCL635 into Phase 2, ABCL575 in Phase 1; two candidates into IND/CTA-enabling.","Cumulative partner programs 104 (+8), molecules in clinic 19 (+3).","Appointed Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer."],"consensus_eps_estimate":-0.1775,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":75128000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107478,"accession_number":"0001703057-26-000003","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbCellera doses first patients in Phase 2 trial of ABCL635 for menopausal vasomotor symptoms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABCL635, a non-hormonal candidate for moderate-to-severe vasomotor symptoms (VMS) of menopause, advances to Phase 2.","Phase 2 is a randomized, double-blind, placebo-controlled study in 80 postmenopausal women.","Top-line clinical results for both Phase 1 and Phase 2 expected in Q3 2026.","Phase 1/2 redesignation based on interim safety, tolerability, and pharmacodynamic data from healthy volunteers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123831,"accession_number":"0001703057-25-000034","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbCellera settles Bruker patent litigation; $36M upfront plus ongoing royalties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Bruker to pay AbCellera $36 million upfront as part of global patent settlement.","Bruker will also pay future royalties on worldwide sales of its Beacon Optofluidic platform.","Settlement resolves all patent litigation between AbCellera and Bruker globally.","No other terms of the license agreement were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123830,"accession_number":"0001703057-25-000032","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"AbCellera dismisses KPMG, appoints EY as auditor for FY2026 after tender","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed KPMG effective after 2025 audit; no disagreements or reportable events in 2023-2025.","EY selected as new independent auditor for FY2026 following a formal tender process.","KPMG's audit opinions for FY2023 and FY2024 were unqualified with no adverse opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123829,"accession_number":"0001703057-25-000029","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera appoints Dr. Stephen Quake to board; Dr. Andrew Lo resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stephen Quake (Stanford professor, Chan Zuckerberg Biohub founder) appointed independent director effective Nov 10, 2025.","Quake joins Audit and Nominating and Corporate Governance committees; qualifies as independent under NASDAQ rules.","Dr. Andrew Lo resigned effective Nov 10, 2025; resignation not due to any disagreement with company.","Lo served on board since Dec 2021; was on Audit and Nominating and Corporate Governance committees.","Quake will receive standard non-employee director compensation per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123828,"accession_number":"0001703057-25-000024","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.","Total revenue $9.0M, up from $6.5M in Q3 2024.","Appointed Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.","Cumulative partner-initiated program starts with downstreams: 103; molecules in clinic: 18.","Total available liquidity $680M ($523M cash/securities + $159M non-dilutive funding)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":30275000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140503,"accession_number":"0001703057-25-000018","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera appoints Sarah Noonberg as first Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sarah Noonberg appointed CMO effective September 10, 2025; she is AbCellera's first CMO.","Noonberg brings over 20 years experience, previously CMO at Metagenomi and other biotechs.","She will lead clinical development of AbCellera's antibody-based therapeutic pipeline.","Appointment marks company transition from discovery to clinical-stage organization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140502,"accession_number":"0001628280-25-038927","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera reports Q2 net loss $34.7M, revenue up 134% YoY; starts Phase 1 for VMS drug ABCL635","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.1M vs $7.3M YoY (134% increase); net loss $34.7M ($0.12 loss per share) vs $36.9M ($0.13) prior year.","First participants dosed in Phase 1 trial of ABCL635 for vasomotor symptoms; initial data expected mid-2026.","Cumulative partner-initiated program starts reached 102 (+9 YoY); molecules in clinic 18 (+4 YoY).","Net loss per share $(0.12) versus $(0.13); R&D expenses $39.2M, G&A $19.0M.","Total liquidity of $753M including $580M cash/securities and $173M in non-dilutive government funding."],"consensus_eps_estimate":-0.1693,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":21320000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158202,"accession_number":"0001628280-25-031219","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AbCellera shareholders approve director elections, auditor ratification, say-on-pay at June 12 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl L.G. Hansen re-elected as Class II director with 141,233,414 for, 444,265 against, 6,760,498 abstain.","Michael Hayden re-elected as Class II director with 121,244,143 for, 417,794 against, 26,796,240 abstain.","Ratification of KPMG as auditor for FY2025 passed: 183,078,982 for, 678,941 against, 241,151 abstain.","Say-on-pay advisory resolution approved: 131,605,595 for, 16,469,354 against, 363,228 abstain, broker non-votes 35,560,807."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158201,"accession_number":"0001628280-25-028529","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera receives Health Canada authorization for Phase 1 trial of ABCL575 for atopic dermatitis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada issued No Objection Letter authorizing Clinical Trial Application for ABCL575, an anti-OX40L antibody.","ABCL575 is an Fc-silenced, half-life extended investigational antibody for moderate-to-severe atopic dermatitis.","Phase 1 trial anticipated to start in Q3 2025, evaluating safety and pharmacokinetics in healthy participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158200,"accession_number":"0001628280-25-025573","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera gets Health Canada nod for Phase 1 trial of ABCL635 for hot flashes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received No Objection Letter from Health Canada for ABCL635, an NK3R antagonist for non-hormonal treatment of vasomotor symptoms.","Phase 1 trial to evaluate safety, PK, and PD in healthy participants and postmenopausal women with moderate-to-severe VMS.","Trial expected to begin in Q3 2025.","ABCL635 is an investigational antibody antagonist targeting NK3R, developed for hot flashes due to menopause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158199,"accession_number":"0001628280-25-025006","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CAFC affirms validity of AbCellera's microfluidic cell culture patent against Bruker challenge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Federal Circuit affirms PTAB decision upholding all claims of U.S. Patent No. 10,087,408.","Patent covers microfluidic devices for culturing and selective recovery of cells.","Bruker Cellular (formerly Berkeley Lights) challenged validity on anticipation/obviousness grounds; both PTAB and CAFC rejected arguments.","Ongoing multi-patent infringement suit between AbCellera and Bruker pending in N.D. California.","AbCellera CEO expects to prove infringement case against Bruker in district court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158198,"accession_number":"0001628280-25-023808","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $4.2M, down 58% from $10.0M in Q1 2024.","Net loss $45.6M ($0.15/share) vs net loss $40.6M ($0.14) year ago.","Announces ABCL635, a first-in-class NK3R antibody for vasomotor symptoms from menopause; Phase 1 expected H2 2025.","Available liquidity ~$810M ($633M cash + $178M government funding).","Cumulative partner program starts 97, clinic molecules 16; R&D spend up to $42.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4235000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176560,"accession_number":"0001628280-25-008650","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera FY2024 revenue $28.8M (down 24%), net loss $0.55/share; plans Phase 1 for two programs in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.","Cash, securities and non-dilutive govt funding total approx. $840M in available liquidity.","Cumulative partner program starts up to 96 (87 in 2023); 16 molecules in clinic (13 in 2023).","Plans to initiate Phase 1 trials for ABCL635 and ABCL575 and start clinical manufacturing facility in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":28833000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176559,"accession_number":"0001628280-25-005983","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbCellera COO Lecault transitions to CTO; COO role dissolved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Feb 18, 2025, Veronique Lecault moved from COO to CTO.","Change agreed mutually, not due to any disagreement with company.","COO position will not be filled and is dissolved.","Lecault remains a director on the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193415,"accession_number":"0001628280-24-045022","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.","R&D expenses rose to $41.0M from $37.9M; G&A expenses increased to $19.1M from $14.4M.","Cumulative partner programs with downstreams reached 95 (up 13% YoY); molecules in clinic grew to 14 from 10.","Expanded Lilly collaboration into immunology, cardiovascular, neuroscience; completed Vancouver HQ consolidation.","Total liquidity over $875M ($670M cash + $205M government funding)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":23783000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209736,"accession_number":"0001628280-24-035229","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q2 net loss $36.9M, revenue down 28% YoY; Lilly collaboration expanded","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $36.9M ($0.13/sh) vs $30.5M loss in Q2 2023; revenue $7.3M down from $10.1M.","Partner-initiated program starts 93 cumulative (+16% YoY); molecules in clinic 14 (+56% YoY).","Expanded Lilly collaboration to immunology, CV, neuroscience; Invetx to be acquired by Dechra for up to $520M.","Abdera's ABD-147 received FDA IND clearance and Fast Track; AbCellera holds low-single-digit royalty and mid-single-digit equity.","Cash and securities $697.6M plus ~$220M non-dilutive government funding; total liquidity >$900M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":17277000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227900,"accession_number":"0001628280-24-028097","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AbCellera shareholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Véronique Lecault and Andrew Lo elected with 167M and 152M votes for, respectively.","Ratification of KPMG as auditor for FY 2024 approved: 212M for, 0.3M against, 0.4M abstain.","Non-binding advisory vote on executive compensation approved: 176.6M for, 7.5M against, 5.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227899,"accession_number":"0001628280-24-021115","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q1 2024 revenue $10.0M, net loss $40.6M; pipeline metrics grow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $10.0M ($9.8M research fees, $0.2M licensing) down 18% from $12.2M in Q1 2023.","Net loss of $40.6M ($0.14 per share) compared to net loss of $40.1M in Q1 2023.","R&D expenses fell to $39.3M from $52.6M; cash & securities $725.3M plus $240M non-dilutive funding.","Cumulative partner-initiated program starts 90 (up 20% YoY) and molecules in clinic 13 (up 44% YoY).","Announced collaborations with Biogen for neurological antibodies and with Viking/ArrowMark to launch biotechs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":9954000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246676,"accession_number":"0001703057-24-000024","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera board member Peter Thiel resigns effective March 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Thiel resigns from AbCellera board for personal reasons; no disagreement with company.","Board size reduced from six to five directors effective March 7, 2024.","Dr. Andrew Lo appointed to Nominating and Corporate Governance Committee replacing Thiel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246675,"accession_number":"0001703057-24-000017","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.","Net loss of $146.4M ($0.51 basic & diluted EPS) vs net income of $158.5M in 2022.","R&D expenses surged to $175.7M (up 63% YoY) on program and platform investments.","Cumulative partner-initiated program starts reached 87; 13 molecules in clinic.","Advanced two internal programs (ABCL635, ABCL575) into IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":38025000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264110,"accession_number":"0001703057-23-000047","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbCellera cuts ~10% of workforce in reorganization; estimates $2.5M cash cost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction impacts approximately 10% of employees to focus on clinical development and strategic partnerships.","Estimated $2.5 million in cash expenses from the workforce reduction.","Company reports over $1 billion in available liquidity, sufficient for strategy beyond 3 years.","Reorganization aims to increase operational efficiency and prioritize internal drug development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264109,"accession_number":"0001703057-23-000038","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.","Net loss of $28.6M ($0.10 loss per share) vs net earnings of $26.6M ($0.09 EPS) in Q3 2022.","Cumulative partnered program starts reached 110, up 20% YoY; 10 molecules in clinic.","Two AbCellera-led programs advanced into IND-enabling studies.","Cash, cash equivalents, and marketable securities $813.0M; R&D expenses $37.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":28846000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264108,"accession_number":"0001703057-23-000034","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbCellera takes ownership of anti-OX40L antibody from EQRx for autoimmune therapy","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Acquired rights to an antibody drug candidate targeting Ox40 ligand from EQRx collaboration.","Candidate is being developed for atopic dermatitis and other autoimmune/inflammatory indications.","AbCellera is advancing the candidate into IND-enabling studies; updates to follow.","No financial terms of the asset transfer were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281349,"accession_number":"0001703057-23-000020","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.","Net loss $30.5M ($0.11/sh) vs net loss $6.8M ($0.02/sh) in Q2 2022; R&D spending rose to $36.5M.","Cash, equivalents and marketable securities $822.9M; secured $220M in strategic financing from Canadian govts.","Cumulative partnered program starts up 20% YoY to 106; 9 molecules advanced to clinic vs 6 a year ago.","Total programs under contract 177 with 41 partners, up from 164 and 38 a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":22248000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300148,"accession_number":"0001703057-23-000014","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AbCellera shareholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John S. Montalbano elected with 167.3M for, 11.0M against; Peter Thiel with 131.2M for, 47.0M against.","Ratification of KPMG as auditor approved: 201.0M for, 0.3M against, 0.2M abstain.","Non-binding say-on-pay compensation approved: 159.4M for, 18.6M against, 0.4M abstain.","Total shares outstanding at record date: 288.7M; broker non-votes on director and say-on-pay: 23.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300147,"accession_number":"0001703057-23-000011","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"AbCellera enters $701M co-investment with Canadian, BC governments for antibody drug development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CA$701M co-investment: AbCellera invests CA$401M, Canada CA$225M, BC CA$75M over 8 years.","Builds capabilities to develop antibody drugs from target identification through Phase 1 clinical trials.","Initial focus on cancer and immune diseases; plans to initiate up to 17 new drug development programs.","Expected to create hundreds of new high-skilled jobs in Canada across computer science, life sciences, and manufacturing.","Government contributions include repayable and conditionally repayable portions starting in 2032-2033."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300146,"accession_number":"0001703057-23-000005","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.","EPS loss $0.14 basic/diluted versus EPS profit $0.59 basic/0.54 diluted a year ago.","Partnered program starts reached 101 cumulative (up 20% YoY); 9 molecules in clinic (up from 6).","R&D spending rose to $52.6M from $26.4M; cash and marketable securities $821.5M.","Management highlighted T-cell engager platform progress; no guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":12192000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320203,"accession_number":"0001564590-23-003427","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"AbCellera discloses minimal SVB exposure of <$15,000 for credit card","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash at Silicon Valley Bank is less than $15,000 USD, used solely to secure a corporate credit card.","No other cash deposits or securities held at SVB.","Company states it has no material exposure due to its relationship with SVB.","Disclosure addresses investor concerns following SVB's collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320202,"accession_number":"0001564590-23-002126","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.","Royalties from COVID antibodies bamlanivimab/bebtelovimab were $443M; EUA for bebtelovimab suspended in Q4.","Partnership business: 23 new program starts, cumulative 101; 174 programs under contract with 40 partners.","Q4 net loss $29.9M; cash and marketable securities $886.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":485424000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338350,"accession_number":"0001564590-22-037057","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.","Bebtelovimab royalties contributed $93.3M; research fees $7.5M, milestones $0.4M, licensing $0.2M.","Cumulative program starts reached 92, up 33% from 69 in Q3 2021; partners increased to 38.","Cash, cash equivalents and marketable securities stood at $868M.","R&D expenses $26.6M (up 52% YoY) reflecting continued investment in discovery engine."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":463879000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355706,"accession_number":"0001564590-22-028771","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.","Net loss $6.8M ($0.02/share) vs loss $2.3M ($0.01/share) in prior year, driven by higher R&D and G&A investments.","Added 4 program starts in Q2, cumulative 88 (+47% YoY); total programs under contract 164 (+19% YoY).","Six molecules cumulatively advanced to clinic, up from 4 at Q2 2021.","Cash & marketable securities $1.022B; R&D expenses $26.7M (+78% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":362497000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355705,"accession_number":"0001564590-22-025922","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera CBO Neil Berkley departs; separation deal includes salary continuation, equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Berkley left as Chief Business Officer effective June 29, 2022.","Receives 12 months base salary ($450,000/yr) paid over 12 months, plus $173,710 cash payment.","AbCellera accelerates vesting of 17,500 RSUs; shares issued on Aug 11, 2022 after trading restriction.","Company pays COBRA premiums through July 1, 2023 or earlier if new job obtained.","Separation agreement includes non-disparagement, non-solicitation, and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355704,"accession_number":"0001564590-22-025392","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AbCellera loses Chief Business Officer Neil Berkley effective June 29, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Berkley departed as Chief Business Officer effective June 29, 2022; not due to any disagreement with the Company.","Berkley qualifies for severance benefits under the Company's Executive Severance Plan (terms previously disclosed in proxy statement).","No successor named in the filing; departure is effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373965,"accession_number":"0001564590-22-024914","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.","Delivery begins immediately and completes by August 5, 2022; option for 350,000 more doses by Sep 14, 2022.","Bebtelovimab maintains neutralization against Omicron variants BA.2.12.1 and BA.4/BA.5, plus all known variants.","Existing supply plus new purchase expected to meet U.S. demand through late August 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373964,"accession_number":"0001564590-22-023707","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AbCellera shareholders elect Hansen and Hayden as Class II directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl G. Hansen re-elected with 140.1M for, 32.2M against; Michael Hayden elected with 147.0M for, 25.3M against.","KPMG ratified as independent auditor for FY 2022: 202.0M for, 0.4M against, 10.7M abstain.","Non-binding say-on-pay approved: 167.8M for, 4.4M against, 10.7M abstain.","Advisory vote favored one-year frequency for future say-on-pay: 171.7M for one year.","Total outstanding shares: 284.5M; broker non-votes of 30.2M on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373963,"accession_number":"0001564590-22-019285","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).","Royalties from bamlanivimab/bebtelovimab contributed $307M of total revenue.","Cumulative program starts reached 84 (up 56% YoY); discovery partners grew to 36 from 29.","Cash, cash equivalents and marketable securities stood at $786.1M.","R&D expenses rose to $26.4M from $12.4M YoY, driven by platform investment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":316581000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392594,"accession_number":"0001564590-22-006755","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.","Net earnings $153.5M ($0.56 basic EPS) vs. $118.9M ($0.53) in 2020; diluted EPS $0.48.","Ended year with $723M in cash and marketable securities; 26 new program starts (78 cumulative).","Q4 revenue $139.3M (37% of FY total), net earnings $59.9M ($0.21 basic EPS).","Five molecules now in clinic (up from one); acquired TetraGenetics for transmembrane protein targets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":375203000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392593,"accession_number":"0001564590-22-005256","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.","Neutralizes Omicron including BA.2 and all known variants; binds rarely mutated spike region.","Second AbCellera antibody from Lilly collaboration; dosage 175 mg IV injection.","U.S. government agreed to buy up to 600,000 doses by March 2022, option for 500,000 more.","CEO Hansen highlights potency; previous antibody bamlanivimab also received EUA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410960,"accession_number":"0001564590-21-059570","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AbCellera appoints Andrew Lo as independent director; John Hamer resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew W. Lo, Ph.D., appointed as independent director effective December 7, 2021.","Lo will serve on Audit and Compensation Committees; he is an MIT professor and TIME 100 honoree.","John Hamer, Ph.D., managing partner at DCVC Bio, resigned from the board effective immediately.","Hamer had served on the board since 2018, including on Audit and Compensation Committees.","CEO Carl Hansen thanked Hamer for his guidance and welcomed Lo for his financial/biomedical expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410959,"accession_number":"0001564590-21-059298","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbCellera appoints Neil Aubuchon as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Aubuchon named CCO effective December 2, 2021; will lead commercial strategy and partnership evaluation.","Aubuchon brings over 20 years experience from Amgen, Lilly, and Santen, including global marketing roles.","CEO Carl Hansen cited Aubuchon's commercial experience as key to expanding AbCellera's deal structures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410958,"accession_number":"0001564590-21-055806","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.","Net loss $21.4M ($0.08 loss per share) vs net loss $2.7M ($0.02 loss) in Q3 2020.","Cumulative program starts 69, up 35% YoY; partners increased to 35; 5 molecules in the clinic.","Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.","Post-quarter: Eli Lilly ordered 614K additional doses of bamlanivimab with etesevimab; shipments resumed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":235872000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410957,"accession_number":"0001564590-21-054498","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.","Total agreement value is $1.29 billion for bamlanivimab with etesevimab, discovered by AbCellera.","The antibody therapy has treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.","AbCellera receives royalties from Lilly on sales of bamlanivimab and etesevimab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429730,"accession_number":"0001564590-21-048621","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera: EU Joint Procurement for up to 220,000 doses of bamlanivimab/etesevimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EC and Lilly agree to supply up to 220,000 doses of bamlanivimab plus etesevimab for COVID-19 in EU/EEA patients 12+ at risk.","Therapy neutralizes Delta variant causing >95% of new EU/EEA infections.","In US, therapy treated >535,000 patients; estimated 25,000 hospitalizations and 10,000 lives saved.","Participating EU/EEA countries can purchase directly from Lilly after national or EU authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429729,"accession_number":"0001564590-21-048042","cik":1703057,"company_name":"AbCellera Biologics Inc.","ticker":"ABCL","form_type":"8-K","filed_at":"2021-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbCellera acquires TetraGenetics for $12.5M upfront to boost antibody discovery","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration of $12.5M; additional technical, development, and commercial milestones possible.","TetraGenetics specializes in recombinant ion channels, GPCRs, and other transmembrane proteins.","Acquisition integrates TetraGenetics' protein expression platform into AbCellera's antibody discovery stack.","Deal aims to unlock antibody therapies against difficult-to-drug transmembrane targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1726897886.9999998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-15T23:59:59+00:00|429729"}